The Blood-Brain Barrier Technologies Market in Latin America is expected to progress at a healthy CAGR from 2021 to 2026.
The brain is one of the largest and most intricate organs in the human body. It consists of 100 billion nerves that communicate with 100 trillion synapses. It is made up of the midbrain, hindbrain, and forebrain. It is responsible for movement and thought produced by the body. It has its own security system-a filtering mechanism consisting of blood vessels that allow entry of essential nutrients at the same time blocking other substances-known as the blood-brain barrier.
The blood-brain barrier is a semi-permeable dynamic interface that separates the capillaries which carry blood to the brain and spinal cord tissue by blocking the passage of certain substances. It is formed by highly specialized endothelial cells. The vessels of the blood-brain barrier are made up of specialized endothelial cells which lines brain capillaries from the vascular system which lack the fenestration of pores and allow rapid exchange of molecules between vessels and tissues. The blood-brain barrier protects the neural tissue from harmful chemicals and maintains a stable environment.
However, this barrier is so effective at blocking the entry of foreign substances that it often prevents penetration of life-saving drugs to address issues like injuries and diseases. Therefore, the discovery of new methods allowing the effective delivery of drugs and bio-macromolecules to the central nervous system (CNS) is of immense importance for the treatment of neurodegenerative disorders. Neurodegeneration and neuroinflammation are major events in CNS disorders like Parkinson's disease, stroke, Alzheimer's disease, and multiple sclerosis. But still, the drugs for CNS treatment, like neurotrophic factors, including BDNF, EPO (erythropoietin), and anti-inflammatory antibodies (e.g., Enbrel and Remicade), do not cross the blood-brain barrier ineffective therapeutic quantities.
Growing prevalence of neurological diseases like Parkinson’s disease, meningitis, multiple sclerosis, and encephalitis, augmenting geriatric population, rising healthcare expenditure, increasing investment in R&D for the development of new drugs and delivery devices, growing awareness about healthcare, and a rising number of initiatives by various governments and affiliated associations are few key factors driving the growth of the market.
On the other hand, intricate regulatory frameworks for the approval of drugs in most countries and inordinate approval time for drugs due to the insufficient knowledge of the brain are primary restraints for the growth of the market.
Latin America expects steady growth in this market throughout the forecast period. Latin American regions like Argentina, Mexico, and Brazil are the most affected countries for any spread of infections and diseases. In recent times these countries got the worst hit due to the rapid spread of the COVID 19 virus. This is due to more ratios of the geriatric and pediatric population across these regions. Although it has sufficient healthcare and infrastructure, the improvement is still needed to be seen and Latin America is yet to develop technologically.
Key players in the market are Bristol-Myers Squibb Company, Pfizer, Inc., biOasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical N.V., Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., NeuroVive Pharmaceutical AB, and ArmaGen.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Latin America
5.1.3 Y-o-Y Growth Analysis, By Geography
5.1.4 Market Attractiveness Analysis, By Geography
5.1.5 Market Share Analysis, By Geography
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
6.4 Rest of Latin America
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allon Therapeutics, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AngioChem Inc.
8.4 CeNeRx BioPharma, Inc
8.5 Bioasis Technologies Inc.
8.6 Ablynx NV
8.7 Capsulution Pharma AG
8.8 International Brain Barriers Society (IBBS)
8.9 Cephalon Inc
8.10 Cognition Pharmaceuticals LLC
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures